Coenzyme Q10 plus piperine,
does it really help with Higher absolute plasma coenzyme Q10 increase and concentration-time area?
research showsThe grade is C with 50 points. In a manufacturer-funded study that randomized twelve healthy men, six per group, the twenty-one-day plasma coenzyme Q10 increase was 1.12±0.20 mg/L with piperine versus 0.85±0.20 mg/L with placebo; AUC was 15.38±2.40 versus 11.81±2.66 mg/L-days. The roughly 30% difference was significant only at twenty-one days with 120 mg/day, while single-dose and fourteen-day 90-mg conditions were null.
ads claimThe claim that piperine optimizes absorption rests on twenty-one-day AUC of 15.38 versus 11.81 mg/L-days, about 30% higher. It does not show an immediate effect or 30% better heart-failure outcomes.
Useful facts when choosing a product
- At twenty-one days, absolute plasma increase was 1.12±0.20 with piperine versus 0.85±0.20 mg/L with placebo, a 0.27 mg/L difference.
- Twenty-one-day AUC was 15.38±2.40 versus 11.81±2.66 mg/L-days, about 30% higher.
- Single-dose and fourteen-day 90-mg conditions were not significant; the positive condition used 120 mg/day for twenty-one days.
- The study used a capsule containing 5 mg BioPerine at least 98% pure, not culinary black pepper.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.coenzyme-q10-plus-purified-piperine.UNK.higher-absolute-plasma-coenzyme-q10-increase-and-concentration-time-area.increase.placeboUnknown > Coenzyme Q10 plus purified piperine > Unknown > Higher absolute plasma coenzyme Q10 increase and concentration-time area > Increase claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Twelve healthy men were randomized six per group to piperine or placebo in a double-blind study. Regimens used coenzyme Q10 90 mg for the single-dose and fourteen-day conditions and 120 mg/day for twenty-one days, each with piperine 5 mg or placebo capsules. At twenty-one days, absolute increase was 1.12±0.20 versus 0.85±0.20 mg/L and AUC was 15.38±2.40 versus 11.81±2.66 mg/L-days. All three authors were affiliated with Sabinsa Corporation, and Sabinsa funded the work. More absorption and better health are different questions, and no trial was identified comparing piperine-added versus piperine-free formulations for heart-failure symptoms, hospitalization, or death. Verdict 1516 is C with 52 points for chronic heart failure, while verdict 958 is D with 31 points for exercise performance in healthy people. Both concern coenzyme Q10 itself rather than added piperine.
Why this is classified as C (50)
The twenty-one-day plasma difference was conventionally large, but it came from one twelve-person short manufacturer study, giving C with 50 points.
Counterpoint. The twenty-one-day result is genuinely positive, while null shorter regimens and healthy male-only enrollment limit generalization.
Rejudgment record. Cross-check applied — Absolute concentrations, AUC, and Sabinsa affiliation and support were checked and separated from verdict 1516 is C with 52 points and verdict 958 is D with 31 points
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Higher plasma coenzyme Q10 exposure at twenty-one days | C | Absolute increase was 1.12 versus 0.85 mg/L and AUC was 15.38 versus 11.81 mg/L-days. |
| Fewer heart-failure symptoms, hospitalizations, or deaths from added piperine | ? | No heart-failure clinical trial comparing piperine-added with piperine-free formulations was identified. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Badmaev et al. 2000 | Randomized double-blind two-group pharmacokinetic study | Twelve healthy men, six per group | Funded by manufacturer Sabinsa Corporation; all authors were Sabinsa-affiliated | Plasma coenzyme Q10 concentration and AUC after single-dose, fourteen-day, and twenty-one-day regimens | At twenty-one days, increase 1.12±0.20 versus 0.85±0.20 mg/L; AUC 15.38±2.40 versus 11.81±2.66 mg/L-days | Core direct absorption evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-04).
Final verification and publication gate: Codex · Evidence date: 2026-08-04 · Corrections: none
Cite this verdict
[Chamgap] Coenzyme Q10 plus piperine x higher plasma coenzyme Q10 — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/coenzyme-q10-piperine-plasma-bioavailability/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.